Australia's most trusted
source of pharma news
Tuesday, 01 July 2025
Posted 12 June 2025 AM
Pfizer claimed one of the first 'wow' moments at this year's American Society of Clinical Oncology (ASCO) meeting with "unprecedented" trial results for its Braftovi combo in metastatic colorectal cancer (mCRC).
The company believes Braftovi in combination with Lilly's Erbitux and chemo regimen mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with mCRC with a BRAF V600E mutation could become a new standard of care.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.